PT  - JOURNAL ARTICLE
AU  - Alejandro Perez
AU  - John R. Bartholomew
TI  - Interpreting the Jupiter trial: Statins can prevent VTE, but more study is needed
AID  - 10.3949/ccjm.77a.09077
DP  - 2010 Mar 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 191--194
VI  - 77
IP  - 3
4099  - http://www.ccjm.org/content/77/3/191.short
4100  - http://www.ccjm.org/content/77/3/191.full
SO  - Cleve Clin J Med2010 Mar 01; 77
AB  - Analysis of a secondary end point of the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) found that a statin reduced the risk of venous thromboembolism (VTE) in apparently healthy people with high levels of C-reactive protein and normal levels of low-density lipoprotein cholesterol (N Engl J Med 2009; 360:1851– 1861). Still, pending more study, statins should not be substituted for proven prophylaxis and anticoagulation, especially for patients with recurrent deep venous thrombosis, hospitalized patients, postoperative patients, and other patients prone to VTE.